Utility of a personalised Bronchiectasis Action Management Plan (BAMP) for children with bronchiectasis: protocol for a multicentre, double-blind parallel, superiority randomised controlled trial

INTRODUCTION: Bronchiectasis is no longer considered rare or irreversible in children, yet it remains relatively under-researched and neglected in respiratory health globally. Bronchiectasis (including chronic suppurative lung disease) causes substantial morbidity for patients and significant impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchant, Julie M, Chang, Anne B, Schutz, Kobi L, Versteegh, Lesley, Cook, Anne, Roberts, Jack, Morris, Peter S, Yerkovich, Stephanie T, McCallum, Gabrielle B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Respiratory Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704965/
https://www.ncbi.nlm.nih.gov/pubmed/34937712
http://dx.doi.org/10.1136/bmjopen-2021-049007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704965/
https://www.ncbi.nlm.nih.gov/pubmed/34937712
http://dx.doi.org/10.1136/bmjopen-2021-049007

Ejemplares similares